The closest we've come to removing plaques, I should mention, is aducanumab, which does seem to reduce beta, but has little to no effect on even slowing cogniti

The closest we've come to removing plaques, I should mention, is aducanumab, which does seem to reduce beta, but has little to no effect on even slowing cognitive decline, much less stopping or reversing it. Nonetheless, the FDA has approved this drug, paving the way for Biogen to charge $56K a year for the treatment. https://n.neurology.org/content/98/15/619 https://n.neurology.org/content/98/15/619